| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2138107 | Leukemia Research | 2009 | 5 Pages |
Abstract
Cytogenetic analysis after induction chemotherapy provides meaningful information especially in patients with intermediate-risk karyotypes. Patients with a persisting abnormal karyotype must be regarded as high-risk patients who should receive intensified treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sebastian Balleisen, Andrea Kuendgen, Barbara Hildebrandt, Rainer Haas, Ulrich Germing,